Geron drops brain cancer drug, to cut jobs

(Reuters) – Geron Corp confirmed it will discontinue development of an experimental drug to treat cancer that has spread to the brain from elsewhere in the body and also cut about 40 percent of its workforce, after patients failed to respond to the drug in a mid-stage study. The company said it will now focus on the development of another drug candidate, imetelstat, as a treatment for blood cancers and some types of solid tumors. …